康泰医学(300869) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥183,239,114.02, a decrease of 29.53% compared to ¥260,008,877.55 in the same period last year[3] - Net profit attributable to shareholders was ¥73,307,986.92, down 36.15% from ¥114,813,438.90 year-on-year[3] - Total operating revenue for Q1 2022 was ¥183,239,114.02, a decrease of 29.5% compared to ¥260,008,877.55 in the same period last year[27] - Net profit for Q1 2022 was ¥73,307,986.92, down 36.3% from ¥114,813,438.90 year-over-year[30] - Basic earnings per share for Q1 2022 was ¥0.1825, compared to ¥0.2858 in the previous year, reflecting a decline of 36.1%[30] - The company reported a decrease in comprehensive income to ¥72,474,343.11 from ¥115,097,608.19 in the previous year, a decline of 37.0%[30] - Other income for Q1 2022 was ¥2,920,431.26, down 39.7% from ¥4,842,675.68 in the previous year[27] Cash Flow - The net cash flow from operating activities increased significantly by 1,359.73%, reaching ¥35,551,530.90 compared to ¥2,435,481.89 in the previous year[3] - Cash flow from operating activities generated a net inflow of ¥35,551,530.90, a significant increase from ¥2,435,481.89 in the same quarter last year[33] - The cash flow from operating activities decreased by 18.47% to ¥22,025.59 million compared to ¥27,015.72 million in the previous year[10] - The net cash flow from financing activities was -$20.34 million, an improvement from -$68.15 million in the previous period[36] - The net increase in cash and cash equivalents was ¥761.05 million, a significant improvement from a decrease of ¥18,537.09 million in the same period last year[10] - The ending balance of cash and cash equivalents was $606.18 million, down from $627.77 million year-over-year[36] Assets and Liabilities - Total assets as of March 31, 2022, were ¥2,865,183,146.81, reflecting a 2.73% increase from ¥2,789,042,837.15 at the end of the previous year[3] - The company's total assets amount to CNY 2,865,183,146.81, an increase from CNY 2,789,042,837.15 at the beginning of the year[23] - The total current assets are CNY 1,452,883,038.19, up from CNY 1,352,138,789.63 at the start of the year[20] - The total liabilities stand at CNY 971,980,592.73, slightly increased from CNY 968,988,361.04[23] - The company has a non-current asset total of CNY 1,412,300,108.62, down from CNY 1,436,904,047.52[22] - Cash and cash equivalents are reported at CNY 608,208,448.45, down from CNY 623,983,067.34[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 48,578, with the top 10 shareholders holding 66.84% of the shares[11] - The largest shareholder, Hu Kun, holds 46.84% of the shares, totaling 188,189,252 shares[11] Research and Development - Research and development expenses rose by 38.66% to ¥1,945.62 million, driven by increased investment in R&D[7] - Research and development expenses increased to ¥19,456,247.08, up 38.5% from ¥14,032,060.67 year-over-year[27] Government Subsidies - The company received government subsidies amounting to ¥922,218.20 during the reporting period[4] Inventory and Accounts Receivable - The company reported a significant increase in accounts receivable by 47.97%, totaling ¥97,964.60 million due to shipments not yet settled[7] - Accounts receivable increased to CNY 97,964,620.18 from CNY 66,207,631.26[20] - The company reported a decrease in inventory to CNY 414,302,534.63 from CNY 418,692,933.45[20] Other Financial Information - The company did not report any investment income for Q1 2022, compared to ¥426,712.33 in the same period last year[30] - Net cash flow from investing activities was -$27.46 million, a decrease from -$113.94 million year-over-year[36] - Cash inflow from financing activities totaled $413.85 million, compared to $452.38 million in the previous period[36] - Cash outflow from financing activities was $434.20 million, up from $520.53 million year-over-year[36] - The impact of exchange rate changes on cash and cash equivalents was $19.86 million, contrasting with a negative impact of -$5.72 million last year[36] Audit Information - The company’s first quarter report was not audited[37]